Entera Bio Ltd. (ENTX) Stock Score, Valuation & Financial Research

Entera Bio Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ENTX

Entera Bio Ltd. does not currently have a complete Wall Street Score. The stored market price is USD 2.53. These figures are a research snapshot, not a buy or sell recommendation.

What Entera Bio Ltd. does

Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Entera Bio is a clinical-stage biotechnology company that generates no commercial revenue. It operates by developing proprietary oral delivery technology for peptides and protein replacement therapies, currently funding its research and development activities through capital raises and strategic collaborations.

Products and services

  • The company is developing a pipeline of oral peptide candidates, primarily EB613 (oral PTH) for osteoporosis and EB618 (oral oxyntomodulin) for metabolic syndromes.

Customer types

Clinical trial participants.

Suppliers, materials and equipment

  • Contract Research Organizations and Contract Manufacturing Organizations — The company relies on third-party service providers for clinical trial management, drug substance manufacturing, and formulation development; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • OPKO Health, Inc. — A collaboration and license agreement established in 2025 to develop oral oxyntomodulin (GLP-1/glucagon) for the treatment of obesity and metabolic syndromes. Source

Business strengths to evaluate

  • Proprietary oral delivery platform for peptides Source
  • FDA alignment on Phase 3 primary endpoint for EB613 Source

Business risks and research considerations

  • History of operating losses and lack of commercial revenue Source
  • Dependence on successful clinical trial outcomes and regulatory approvals Source
  • Reliance on third-party manufacturers and service providers Source

Sources: Company research source · OPKO Health, Inc.

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ENTX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.53
Market capitalization:
124.7M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -17.03M
Free cash flow:
USD -7.48M
Cash:
USD 11.31M
Total debt:
USD 425K
EPS:
USD -0.35

What stands out

  • Reported year-over-year revenue growth is -100.0%.
  • Free cash flow is USD -7.48M, negative for the stored period.
  • The balance sheet shows USD 11.31M of cash versus USD 425K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 10.88M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ENTX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • What is driving ENTX's revenue decline, and does the latest filing suggest the weakness is temporary or structural?
  • How long can ENTX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ENTX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ENTX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of ENTX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research ENTX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.